3. Subsequent Events	9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	On October 16, 2018, the Company has announced the start of a small research project in the field of cancer immunotherapy together with eTheRNA N.V., a clinical stage biotech company developing novel mRNA cancer immunotherapy. The objective of the project is to evaluate the suitability of Mymetics’ proprietary virosome vaccine delivery technology in combination with mRNA, specifically eTheRNA’s proprietary TriMix mRNA. eTheRNA will evaluate the duration and intensity of mRNA expression in vivo and the induction of antigen specific T cells and antitumor efficacy upon therapeutic vaccination in selected tumor models. Mymetics’ virosome particles have shown to be able to trigger good specific T cell responses as virosomes are able to be absorbed and processed by dendritic cells, thereby presenting specific antigens to T-Cells to promote immunity against these foreign antigens. The project is the first step in determining if there is a basis for a further collaboration between Mymetics and eTheRNA, of short duration and without immediate commercial impact for either of the parties involved. In November, 2018, the Company agreed with Round Enterprises Ltd and Eardley Holding AG the issuance of promissory notes with a total combined value of E800, with an annual interest rate of 2.5% and a maturity date which is the later of (i) June 30, 2019, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes. The total amount of E800 has been received on November 2018.

3. Subsequent Events

9 Months Ended

Sep. 30, 2018

On October 16, 2018, the Company has announced the start of a small research project in the field of cancer immunotherapy together with eTheRNA N.V., a clinical stage biotech company developing novel mRNA cancer immunotherapy. The objective of the project is to evaluate the suitability of Mymetics’ proprietary virosome vaccine delivery technology in combination with mRNA, specifically eTheRNA’s proprietary TriMix mRNA. eTheRNA will evaluate the duration and intensity of mRNA expression in vivo and the induction of antigen specific T cells and antitumor efficacy upon therapeutic vaccination in selected tumor models.

Mymetics’ virosome particles have shown to be able to trigger good specific T cell responses as virosomes are able to be absorbed and processed by dendritic cells, thereby presenting specific antigens to T-Cells to promote immunity against these foreign antigens.

The project is the first step in determining if there is a basis for a further collaboration between Mymetics and eTheRNA, of short duration and without immediate commercial impact for either of the parties involved.

In November, 2018, the Company agreed with Round Enterprises Ltd and Eardley Holding AG the issuance of promissory notes with a total combined value of E800, with an annual interest rate of 2.5% and a maturity date which is the later of (i) June 30, 2019, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes. The total amount of E800 has been received on November 2018.